Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Digoxin

FDA-approved product (injectable, injection), marketed as Digoxin, Digoxin Pediatric, Lanoxicaps and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Digoxin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrial fibrillation
  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Digitalis glycosides
FDA pharmacologic class
Cardiac Glycoside FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Digoxin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Digoxin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin

    NCT05357911 · start 2021-07-13

    Registered record
    Registry ID
    NCT05357911
    Conditions
    Solid Tumor
    Interventions
    AB-106, digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-07-13
    Completion
    2021-12-03
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionAB-106, digoxin
    PhasePhase 1
    Registry statusCompleted

  • FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

    NCT04141995 · start 2021-02-12

    Registered record
    Registry ID
    NCT04141995
    Conditions
    Pancreas Cancer; Adenocarcinoma of the Pancreas
    Interventions
    Digoxin; 5Fluorouracil; Calcium Leucovorin; Irinotecan; Oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-02-12
    Completion
    2025-05-13
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreas Cancer; Adenocarcinoma of the Pancreas
    InterventionDigoxin; 5Fluorouracil; Calcium Leucovorin; Irinotecan +1 more
    PhasePhase 2
    Registry statusTerminated

  • Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention

    NCT04778787 · start 2021-01-01

    Registered record
    Registry ID
    NCT04778787
    Conditions
    Congestive Heart Failure
    Interventions
    Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2022-08-01
    Enrolment
    370

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongestive Heart Failure
    InterventionStandard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
    PhasePhase 4
    Registry statusCompleted

  • Bioequivalence Study of Digoxin Tablet in Healthy Subjects

    NCT06546215 · start 2020-07-05

    Registered record
    Registry ID
    NCT06546215
    Conditions
    Heart Failure
    Interventions
    Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-07-05
    Completion
    2021-01-23
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionDigoxin
    PhasePhase 1
    Registry statusCompleted

  • A Study of JNJ-70033093 and Digoxin in Healthy Participants

    NCT04206488 · start 2020-01-09

    Registered record
    Registry ID
    NCT04206488
    Conditions
    Healthy
    Interventions
    JNJ-70033093; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-09
    Completion
    2021-06-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionJNJ-70033093; Digoxin
    PhasePhase 1
    Registry statusCompleted

  • Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing

    NCT03433833 · start 2019-11-10

    Registered record
    Registry ID
    NCT03433833
    Conditions
    Polycythemia; Familial; Erythrocytosis; Familial; VHL Gene Mutation; HIF-2alpha Erythrocytosis; PHD2 Erythrocytosis; Chuvash Erythrocytosis
    Interventions
    Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2019-11-10
    Completion
    2024-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycythemia; Familial; Erythrocytosis; Familial +4 more
    InterventionDigoxin
    PhasePhase 1
    Registry statusWithdrawn

  • Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI

    NCT03810417 · start 2019-07-22

    Registered record
    Registry ID
    NCT03810417
    Conditions
    Acute Kidney Injury
    Interventions
    Digoxin Antibodies Fab Fragments; Placebo; Baseline EO > 360 pM; EO < 360 pM
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-07-22
    Completion
    2024-04-30
    Enrolment
    267

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury
    InterventionDigoxin Antibodies Fab Fragments; Placebo; Baseline EO > 360 pM; EO < 360 pM
    PhasePhase 4
    Registry statusCompleted

  • Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

    NCT03889795 · start 2019-06-05

    Registered record
    Registry ID
    NCT03889795
    Conditions
    Advanced Pancreatic Cancer; Advanced Solid Tumor
    Interventions
    Metformin; Simvastatin; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2019-06-05
    Completion
    2027-12-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Pancreatic Cancer; Advanced Solid Tumor
    InterventionMetformin; Simvastatin; Digoxin
    PhasePhase 1
    Registry statusActive not recruiting

  • Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction

    NCT04308031 · start 2018-08-26

    Registered record
    Registry ID
    NCT04308031
    Conditions
    Atrial Fibrillation; Ivabradine; Heart Failure
    Interventions
    Ivabradine 5 mg [Corlanor]; Digoxin 0.25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-08-26
    Completion
    2020-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Ivabradine; Heart Failure
    InterventionIvabradine 5 mg [Corlanor]; Digoxin 0.25 mg
    PhasePhase 3
    Registry statusUnknown

  • A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

    NCT03363815 · start 2017-12-04

    Registered record
    Registry ID
    NCT03363815
    Conditions
    Heathy Volunteer
    Interventions
    CC-90001; Omeprazole; Midazolam; Warfarin; Vitamin K; Rosuvastatin; Metformin; Digoxin; Nintedanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-12-04
    Completion
    2018-07-29
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeathy Volunteer
    InterventionCC-90001; Omeprazole; Midazolam; Warfarin +5 more
    PhasePhase 1
    Registry statusCompleted

  • Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

    NCT03113071 · start 2017-06-02

    Registered record
    Registry ID
    NCT03113071
    Conditions
    Acute Myeloid Leukemia; Myelodysplastic Syndromes
    Interventions
    Decitabine; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2017-06-02
    Completion
    2019-03-11
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Myelodysplastic Syndromes
    InterventionDecitabine; Digoxin
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam

    NCT03043248 · start 2017-02-06

    Registered record
    Registry ID
    NCT03043248
    Conditions
    Healthy
    Interventions
    TRK-700; Digoxin; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-02-06
    Completion
    2017-05-21
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTRK-700; Digoxin; Midazolam
    PhasePhase 1
    Registry statusCompleted

  • Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)

    NCT02624765 · start 2016-02

    Registered record
    Registry ID
    NCT02624765
    Conditions
    Fetal Atrial Flutter Without Hydrops; Fetal Supraventricular Tachycardia Without Hydrops; Fetal Supraventricular Tachycardia With Hydrops
    Interventions
    Digoxin (monotherapy); Sotalol (monotherapy); Flecainide (monotherapy); Digoxin (dual therapy); Sotalol (dual therapy); Flecainide (dual therapy)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02
    Completion
    2024-03-31
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFetal Atrial Flutter Without Hydrops; Fetal Supraventricular Tachycardia Without Hydrops; Fetal Supraventricular Tachycardia With Hydrops
    InterventionDigoxin (monotherapy); Sotalol (monotherapy); Flecainide (monotherapy); Digoxin (dual therapy) +2 more
    PhasePhase 3
    Registry statusCompleted

  • Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

    NCT02578277 · start 2015-11-09

    Registered record
    Registry ID
    NCT02578277
    Conditions
    HIV Infections
    Interventions
    CYP and transporter probe substrates; BMS-955176; BMS-955176 plus CYP and transporter probe substrates
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-11-09
    Completion
    2015-12-23
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCYP and transporter probe substrates; BMS-955176; BMS-955176 plus CYP and transporter probe substrates
    PhasePhase 1
    Registry statusCompleted

  • Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

    NCT02620384 · start 2015-10-01

    Registered record
    Registry ID
    NCT02620384
    Conditions
    Acute Decompensated Heart Failure
    Interventions
    Experimental: Placebo; Experimental: Metolazone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-10-01
    Completion
    2017-12-29
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Decompensated Heart Failure
    InterventionExperimental: Placebo; Experimental: Metolazone
    PhasePhase 3
    Registry statusTerminated